Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Smoking Cessation

Therapeutic area intelligence for Smoking Cessation with 8 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 8
Catalysts: 0
Companies: 3

Companies

Dr. Reddy's Labs →

Assets

Infrastructure →

varenicline →

Recent signals(8)

RegulatoryJuly 29, 2026

FDA Accepts Supplemental Application for ZYBAN by GlaxoSmithKline

The FDA has accepted a supplemental application for ZYBAN, an established smoking cessation aid.

Regulatory

July 23, 2026

FDA Approves Supplemental Applications for ZYBAN by GlaxoSmithKline

The FDA has approved supplemental applications for ZYBAN (bupropion hydrochloride) submitted by GlaxoSmithKline.

CompetitiveJuly 18, 2026

Infrastructure Proposal for mHealth Interventions in Cancer Patient Smoking Cessation

A new infrastructure is being proposed to support the development of mobile health tools aimed at reducing smoking among cancer patients.

ClinicalJuly 15, 2026

Study on mHealth Smoking Cessation for African Americans with HIV/AIDS Initiated

A study is underway to evaluate an mHealth intervention for smoking cessation among Black individuals with HIV/AIDS.

CompetitiveJuly 14, 2026

FDA Grants AP Status for Nicotine Polacrilex by Dr. Reddy's Labs

The FDA has granted Abbreviated Approval (AP) status for ANDA215276, a nicotine polacrilex product from Dr. Reddy's Labs.

StrategyJuly 12, 2026

FDA Approves Varenicline Tartrate ANDA219382 by Somerset Therap LLC

The FDA has approved the ANDA for Varenicline Tartrate submitted by Somerset Therap LLC.

ClinicalJuly 11, 2026

Study Evaluates Tobacco Treatment Strategies for Cancer Survivors

A two-arm pragmatic cluster randomized trial is underway to compare the effectiveness of informatics-enabled strategies for tobacco treatment in cancer survivors.

ClinicalJune 18, 2026

Pilot Study on Text-Based Contingency Management for Smoking Cessation Engagement

A pilot study is assessing the feasibility of a text-based contingency management intervention to enhance engagement in smoking cessation treatment.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.